Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40JMN | ISIN: US17248W3034 | Ticker-Symbol:
NASDAQ
24.04.25
21:59 Uhr
4,350 US-Dollar
+0,065
+1,52 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CINGULATE INC Chart 1 Jahr
5-Tage-Chart
CINGULATE INC 5-Tage-Chart

Aktuelle News zur CINGULATE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.04.Cingulate secures $3m to advance once-daily anxiety treatment3
09.04.Cingulate Inc. - 8-K, Current Report2
09.04.Cingulate Inc.: Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)4
03.04.Cingulate Inc.: Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-13013
27.03.Cingulate Inc. - 10-K, Annual Report4
26.03.Cingulate reports FY results4
CINGULATE Aktie jetzt für 0€ handeln
26.03.Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved229In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025$17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date...
► Artikel lesen
26.03.Cingulate Inc. - 8-K, Current Report4
04.03.Cingulate Inc.: Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025133Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2 CTx-1301 is the First, True, Once-Daily Stimulant Medication to Treat ADHD Over the Entire Active Day KANSAS CITY...
► Artikel lesen
04.03.Cingulate Inc. - 8-K, Current Report-
03.02.Cingulate Inc. - 8-K, Current Report1
24.01.Cingulate Inc. - 8-K, Current Report5
07.01.Cingulate Inc. - 8-K, Current Report5
23.12.24Cingulate Inc.: Cingulate Completes Financing Transaction for Net Proceeds of $5,000,0006
23.12.24Cingulate Inc. - 8-K, Current Report-
07.11.24Cingulate Inc.: Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market235KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology...
► Artikel lesen
07.11.24Cingulate Inc. - 10-Q, Quarterly Report14
07.11.24Cingulate Inc. - 8-K, Current Report-
16.08.24Pre-market Movers: Cingulate, Greenland Technologies, Shimmick Corporation, Quantum BioPharma, CI&T1.011BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.20 A.M. ET).In the Green Cingulate Inc. (CING) is up over 89% at $9.08. Greenland...
► Artikel lesen
15.08.24Cingulate Inc.: Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD298KANSAS CITY, Kan., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology...
► Artikel lesen
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1